Meissa Vaccines has raised $30 million to advance a pipeline of vaccines to prevent viral respiratory infections. The series A equips Meissa to run phase 1 and 2 trials of a respiratory syncytial virus (RSV) vaccine while moving other candidates based on its synthetic biology technology toward the clinic.
Read the full article on FierceBiotech.